DUPLICA REAL TIME FACTOR II G20210A. Coagulation disorders
Recently a new polymorphism are identified in the 3’- untranslated region of the prothrombin gene or Factor II, the G20210 transition (FII G20210A) which was found to be associated with an increased prothrombin levels in plasma and an increased risk of venous thrombosis.
DUPLICαRealTime FACTOR II Genotyping Kit was designed to identify a G20210A point mutation in factors II gene that is one of the most common inherited risk factor for Deep Vein Thrombosis.
Samples: EDTA collected peripheral whole blood
DUPLICA REAL TIME FACTOR V G1691A. Coagulation disorders
Resistance to activated protein C (APC) is a genetic factor that increase thrombotic risk. A number of clinical studies show a prevalence of activated protein C resistance of 20-60% among patients with venous thromboembolism
At least 90% of the cases with resistance to activated protein C are explained by a point mutation in the gene for coagulation factor V (Leiden mutation) causing substitution of Arg to Gln at position 506
RealTime FACTOR V Genotyping Kit was designed to identify a G1691A point mutation in factors V gene that is one of the most common inherited risk factor for Deep Vein Thrombosis.
Sample: EDTA collected peripheral whole blood
DUPLICA REAL TIME MTHFR C677T. Coagulation disorders
One of the most common genetic defects of homocystein metabolism is a mutation in the enzyme MTHFR. The most common MTHFR mutation is C677T causing substitution of Ala to Val at position 222 (Ala222Val). This mutation is associated with reduced enzyme activity and elevated total homocystein levels in serum or plasma.
DUPLICαRealTime MTHFR C677T Genotyping Kit was designed to identify C667T point mutation in a gene coding MTHFR enzyme.
|DUPLICA REAL TIME FACTOR II G20210A||Análisis de 32 reacciones|
|DUPLICA REAL TIME FACTOR V G1691A||Análisis de 32 reacciones|
|DUPLICA REAL TIME MTHFR C677T||Análisis de 32 reacciones|